169 related articles for article (PubMed ID: 22550280)
1. Radioiodine scintigraphy with SPECT/CT: an important diagnostic tool for thyroid cancer staging and risk stratification.
Avram AM
J Nucl Med; 2012 May; 53(5):754-64. PubMed ID: 22550280
[TBL] [Abstract][Full Text] [Related]
2. Radioiodine scintigraphy with SPECT/CT: an important diagnostic tool for thyroid cancer staging and risk stratification.
Avram AM
J Nucl Med Technol; 2014 Sep; 42(3):170-80. PubMed ID: 25190758
[TBL] [Abstract][Full Text] [Related]
3. Role of SPECT/CT in differentiated thyroid cancer.
Barwick TD; Dhawan RT; Lewington V
Nucl Med Commun; 2012 Aug; 33(8):787-98. PubMed ID: 22669053
[TBL] [Abstract][Full Text] [Related]
4. Incremental diagnostic value of SPECT/CT with 131I scintigraphy after radioiodine therapy in patients with well-differentiated thyroid carcinoma.
Maruoka Y; Abe K; Baba S; Isoda T; Sawamoto H; Tanabe Y; Sasaki M; Honda H
Radiology; 2012 Dec; 265(3):902-9. PubMed ID: 23012466
[TBL] [Abstract][Full Text] [Related]
5. [SPECT/CT for staging and treatment monitoring in oncology. Applications in differentiated thyroid cancer and liver tumors].
Weber K; Berger F; Mustafa M; Reiser MF; Bartenstein P; Haug A
Radiologe; 2012 Jul; 52(7):646-52. PubMed ID: 22710988
[TBL] [Abstract][Full Text] [Related]
6. Impact of 131I SPECT/spiral CT on nodal staging of differentiated thyroid carcinoma at the first radioablation.
Schmidt D; Szikszai A; Linke R; Bautz W; Kuwert T
J Nucl Med; 2009 Jan; 50(1):18-23. PubMed ID: 19091884
[TBL] [Abstract][Full Text] [Related]
7. Hybrid SPECT/CT Imaging in the Management of Differentiated Thyroid Carcinoma.
Ahmed N; Niyaz K; Borakati A; Marafi F; Birk R; Usmani S
Asian Pac J Cancer Prev; 2018 Feb; 19(2):303-308. PubMed ID: 29479949
[TBL] [Abstract][Full Text] [Related]
8. Can (18)F-FDG-PET/CT be generally recommended in patients with differentiated thyroid carcinoma and elevated thyroglobulin levels but negative I-131 whole body scan?
Bannas P; Derlin T; Groth M; Apostolova I; Adam G; Mester J; Klutmann S
Ann Nucl Med; 2012 Jan; 26(1):77-85. PubMed ID: 22006540
[TBL] [Abstract][Full Text] [Related]
9. [Diagnostics and treatment of differentiated thyroid cancer using nuclear medicine].
Morsing A; Bogsrud TV
Ugeskr Laeger; 2012 Jun; 174(26):1813-6. PubMed ID: 22735115
[TBL] [Abstract][Full Text] [Related]
10. Staging of differentiated thyroid carcinoma using diagnostic 131I SPECT/CT.
Wong KK; Sisson JC; Koral KF; Frey KA; Avram AM
AJR Am J Roentgenol; 2010 Sep; 195(3):730-6. PubMed ID: 20729453
[TBL] [Abstract][Full Text] [Related]
11. Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer.
Lind P; Kohlfürst S
Semin Nucl Med; 2006 Jul; 36(3):194-205. PubMed ID: 16762610
[TBL] [Abstract][Full Text] [Related]
12. Preablation 131-I scans with SPECT/CT contribute to thyroid cancer risk stratification and 131-I therapy planning.
Avram AM; Esfandiari NH; Wong KK
J Clin Endocrinol Metab; 2015 May; 100(5):1895-902. PubMed ID: 25734251
[TBL] [Abstract][Full Text] [Related]
13. Molecular imaging in the management of thyroid cancer.
Wong KK; Dvorak RA; Marzola MC; Grassetto G; Gross MD; Rubello D
Q J Nucl Med Mol Imaging; 2011 Oct; 55(5):541-59. PubMed ID: 22019711
[TBL] [Abstract][Full Text] [Related]
14. Value of ¹³¹I SPECT/CT for the evaluation of differentiated thyroid cancer: a systematic review of the literature.
Xue YL; Qiu ZL; Song HJ; Luo QY
Eur J Nucl Med Mol Imaging; 2013 May; 40(5):768-78. PubMed ID: 23242250
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of Diagnostic Value of SPECT/CT Imaging in Post-radioiodine Therapy in Thyroid Cancer.
Al Hatmi A; Jain A; Mittal AK; Hussain S
Sultan Qaboos Univ Med J; 2022 Feb; 22(1):74-81. PubMed ID: 35299812
[TBL] [Abstract][Full Text] [Related]
16. Diagnostic accuracy of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in differentiated thyroid cancer patients with elevated thyroglobulin and negative (131)I whole body scan: evaluation by thyroglobulin level.
Na SJ; Yoo IeR; O JH; Lin C; Lin Q; Kim SH; Chung SK
Ann Nucl Med; 2012 Jan; 26(1):26-34. PubMed ID: 21971605
[TBL] [Abstract][Full Text] [Related]
17. Imaging in endocrinology: 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in differentiated thyroid carcinoma: clinical indications and controversies in diagnosis and follow-up.
Salvatori M; Biondi B; Rufini V
Eur J Endocrinol; 2015 Sep; 173(3):R115-30. PubMed ID: 25947140
[TBL] [Abstract][Full Text] [Related]
18. Role of [(18)F]-fluorodeoxy-D-glucose positron emission tomography and computed tomography in the early detection of persistent/recurrent thyroid carcinoma in intermediate-to-high risk patients following initial radioactive iodine ablation therapy.
Kim MH; O JH; Ko SH; Bae JS; Lim DJ; Kim SH; Baek KH; Lee JM; Kang MI; Cha BY; Lee KW
Thyroid; 2012 Feb; 22(2):157-64. PubMed ID: 22224820
[TBL] [Abstract][Full Text] [Related]
19. The effect of posttherapy 131I SPECT/CT on risk classification and management of patients with differentiated thyroid cancer.
Grewal RK; Tuttle RM; Fox J; Borkar S; Chou JF; Gonen M; Strauss HW; Larson SM; Schöder H
J Nucl Med; 2010 Sep; 51(9):1361-7. PubMed ID: 20720058
[TBL] [Abstract][Full Text] [Related]
20. Clinical utility of 18F-FDG PET/CT concurrent with 131I therapy in intermediate-to-high-risk patients with differentiated thyroid cancer: dual-center experience with 286 patients.
Lee JW; Lee SM; Lee DH; Kim YJ
J Nucl Med; 2013 Aug; 54(8):1230-6. PubMed ID: 23813775
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
